Liminatus Pharma (LIMN) Change in Account Payables (2024 - 2026)
Liminatus Pharma (LIMN) posted Change in Account Payables of -$14999.0 for Q1 2026, down 147.57% sequentially from $31533.0 in Q4 2025, and up 16.67% YoY from -$12855.7 in Q1 2025.
Liminatus Pharma (LIMN) Change in Account Payables (2024 - 2026) Analysis & Trends
Liminatus Pharma has reported Change in Account Payables for 3 years, with the latest figure at -$14999.0 in Q1 2026.
- Quarterly Change in Account Payables rose 16.67% year-over-year to -$14999.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59466.0 (changed N/A YoY) and the FY2025 annual result came in at -$62467.0, changed N/A from the prior year.
- Change in Account Payables eased to -$14999.0 in Q1 2026 per LIMN's latest filing, from $31533.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $31533.0 in Q4 2025 and troughed at -$83500.0 in Q2 2025.
- A 3-year average of -$13244.3 and a median of -$8499.5 in 2024 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2025 and 2026: Change in Account Payables surged 475.0% in 2025, then rose 16.67% in 2026.
- Over 3 years, Change in Account Payables stood at -$2000.0 in 2024, then surged by 1676.65% to $31533.0 in 2025, then sank by 147.57% to -$14999.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$14999.0, $31533.0, and $7500.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Liminatus Pharma | 256.03 Mn | 256.03 Mn | - | 6,844.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,999.00 |
| Mar 31, 2026 | -14,999.00 |
| Dec 31, 2025 | 31,533.00 |
| Dec 31, 2025 | 31,533.00 |
| Sep 30, 2025 | 7,500.00 |
| Sep 30, 2025 | 7,500.00 |
| Jun 30, 2025 | -83,500.00 |
| Jun 30, 2025 | -83,500.00 |
| Mar 31, 2025 | -18,000.00 |
| Mar 31, 2025 | -18,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |